Integrated left ventricular multi-omics landscape of human cardiometabolic HFpEF
Cardiovascular Research · 05.06.2026 · 122 (8) · 984-1000
DOI: 10.1093/cvr/cvag084 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Cardiovascular Research, online erschienen am 22.04.2026. Verfasst von Federico Capone und 23 weiteren Autor:innen. Beteiligte Einrichtung: Translational Approaches in Heart Failure and Cardiometabolic Disease, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC),…. Hauptthemen laut MEDLINE: Heart Failure, Metabolic Reprogramming, Multiomics, Myocardium. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 69 Literaturangaben. Gefördert von: DZHK, Deutsche Forschungsgemeinschaft, European Research Council.
Abstract (Originalsprache)
Aims
Heart failure with preserved ejection fraction (HFpEF), now the leading form of heart failure, is burdened by high morbidity and mortality, owing to gaps in our understanding of its molecular and pathophysiological mechanisms. The obese/cardiometabolic HFpEF phenotype is particularly prevalent and morbid, and obesity is increasingly recognized as a driver of the syndrome, though the underlying mechanisms distinguishing cardiometabolic HFpEF from obesity remain unclear. Comprehensive multi-omics characterization of left ventricular samples from patients with HFpEF and obesity, compared with obese non-failing counterparts, provides an opportunity to deepen our understanding of the pathophysiology of cardiometabolic HFpEF. Methods and results We applied an integrated multi-omics approach to compare left ventricular (LV) endomyocardial biopsies (EMB) from overweight/obese HFpEF patients (n = 19) and non-failing overweight/obese (NFO) individuals (n = 4). Proteomic, metabolomic, and lipidomic data were integrated with clinical parameters, imaging and invasive haemodynamic to investigate the molecular mechanisms and clinical relevance of metabolic dysregulation in HFpEF. HFpEF patients exhibited distinct proteomic signatures marked by extracellular matrix (ECM) remodelling and impaired energy metabolism compared with NFO individuals. Specifically, HFpEF hearts showed diminished glycolysis, altered glucose metabolism, preserved fatty acid oxidation (FAO) and accumulation of succinate, consistent with myocardial energy deprivation. Changes in purine and pyrimidine metabolism further indicated altered nucleotide homeostasis. Integrative analyses revealed strong correlations between metabolic derangements, ECM proteins expression, and clinical indices of cardiac function and disease severity.
Conclusion
Our findings indicate that metabolic remodelling—particularly dysregulated glycolysis and changes in TCA cycle intermediates —characterize myocardial dysfunction in cardiometabolic HFpEF. Importantly, comprehensive multi-omics analysis of LV EMBs identified HFpEF-specific alterations in cardiac metabolism and remodelling occurring independently from obesity. These insights highlight the interplay between metabolic dysregulation, ECM remodelling, and clinical phenotype in cardiometabolic HFpEF, offering a foundation for targeted metabolic interventions in this syndrome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Translational Approaches in Heart Failure and Cardiometabolic Disease, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Robert-Rössle-Straße 10, 13125 Berlin, Germany.
- Department of Medicine (DIMED), Unit of Internal Medicine III, Padua University Hospital, University of Padua, Padova, Italy.
- Department of Biomedical Sciences, University of Padova, Padova, Italy.
- Heart Center at University of Leipzig, Leipzig, Germany.
- Proteomic and Metabolomics Platform, Berlin Institute for Medical Systems Biology (BIMSB), Max Delbrück Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany.
- Proteomics Platform, Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Berlin, Germany.
ORCID-Profile: Federico Capone, Guido Mastrobuoni, Stefan Kempa, Gabriele G Schiattarella
Förderung
- DZHK
- Deutsche Forschungsgemeinschaft
- European Research Council
- HI-TAC
- Heart Failure Association
- European Society of Cardiology
- HFA Basic and Translational Research
- Pathfinder Cardiogenomics Programme of the European Innovation Council of the European Union
Zitieren
APA
Capone, F., Rommel, K. P., Forbes, M., Fahjen, P., Strocchi, S., Rosch, S., Wang, R., Bode, D., Nambiar, N., Eroglu, T., Padilla, L. S., Morieri, M. L., Liu, L., Farrelly, C., Vacca, A., Mastrobuoni, G., Jung, S., Diezel, S. A., Liévano Contreras, S. V., …, & Schiattarella, G. G. (2026). Integrated left ventricular multi-omics landscape of human cardiometabolic HFpEF. Cardiovascular Research, 122(8), 984-1000. https://doi.org/10.1093/cvr/cvag084
Vancouver
Capone F, Rommel KP, Forbes M, Fahjen P, Strocchi S, Rosch S, et al. Integrated left ventricular multi-omics landscape of human cardiometabolic HFpEF. Cardiovascular Research. 2026;122(8):984-1000. doi:10.1093/cvr/cvag084
BibTeX
@article{Capone2026,
author = {Capone, Federico and Rommel, Karl-Philipp and Forbes, Martin and Fahjen, Pauline and Strocchi, Stefano and Rosch, Sebastian and Wang, Rongling and Bode, David and Nambiar, Natasha and Eroglu, Tolga and Padilla, Leandro Santiago and Morieri, Mario Luca and Liu, Luo and Farrelly, Catherine and Vacca, Antonio and Mastrobuoni, Guido and Jung, Simone and Diezel, Saskia A and Liévano Contreras, Sarah V and Hübner, Norbert and Mertins, Philipp and Kempa, Stefan and Lurz, Philipp and Schiattarella, Gabriele G},
title = {Integrated left ventricular multi-omics landscape of human cardiometabolic HFpEF},
journal = {Cardiovascular Research},
year = {2026},
volume = {122},
number = {8},
pages = {984--1000},
doi = {10.1093/cvr/cvag084}
}
EUVIMED